AIM
EBS icon

Acrospire Investment Management’s Emergent Biosolutions EBS Stock Holding History

Acrospire Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-976
Closed -$33K – 437
2017
Q2 		$33K Buy
+976
New +$30.1K 0.03% 1215
2017
Q1 		– Sell
-788
Closed -$26K – 2268
2016
Q4 		$26K Sell
788
-6,524
-89% -$196K 0.01% 1682
2016
Q3 		$231K Hold
7,312
– – 0.15% 89
2016
Q2 		$206K Buy
7,312
+4,800
+191% +$188K 0.15% 61
2016
Q1 		$91K Buy
+2,512
New +$88.7K 0.06% 393

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Acrospire Investment Management's EBS Position: Q3 2017 in Review

Acrospire Investment Management sold out of Emergent Biosolutions (EBS) in Q3 2017, closing a stake of 976 shares — an estimated $33K sold.

Acrospire Investment Management first reported a position in EBS in Q1 2016 and held it in 5 quarters. The position peaked at $231K in Q3 2016. 198 funds tracked by Wall St. Rank hold EBS as of Q3 2017.

  • Acrospire Investment Management reported no remaining Emergent Biosolutions position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 976 Emergent Biosolutions shares in Q3 2017, an estimated $33K.
  • Acrospire Investment Management first reported a position in Emergent Biosolutions in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Emergent Biosolutions position peaked at $231K in Q3 2016.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.